Con­gress' Chi­na hawks seek to add biotech sup­pli­ers to Pen­ta­gon warn­ing list

Last year
China
FDA+

CBER's Marks points to stock­piles of H5N1 vac­cine as of­fi­cials mon­i­tor re­port­ed hu­man case

Last year
Pharma
FDA+

EU­'s phar­ma leg­isla­tive re­forms 'will scare in­vest­ment away,' Astel­las ex­ec­u­tive says

Last year
Pharma
Law

Gilead part­ners for ball­room danc­ing work­shop on sex­u­al health and HIV pre­ven­tion

Last year
Pharma
Marketing

Eiger files for bank­rupt­cy and will wind down op­er­a­tions af­ter years of set­backs

Last year
People
Pharma

BM­S' con­fir­ma­to­ry tri­al of Kraza­ti hits pri­ma­ry end­point fol­low­ing 2022 ac­cel­er­at­ed ap­proval

Last year
Pharma
FDA+

Liq­uidia wins against Unit­ed Ther­a­peu­tics in patent bat­tle over PAH drug

Last year
Pharma
Law

Omega cuts 35% of work­force; Rhythm, Cer­voMed, Sur­rozen raise new fund­ing

Last year
News Briefing

Caris­ma to lay off staff, drop clin­i­cal CAR-M pro­gram in fa­vor of sec­ond can­di­date

Last year
People
R&D

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Last year
R&D

FDA de­lays de­ci­sion on Ap­plied Ther­a­peu­tics’ rare meta­bol­ic dis­ease drug

Last year
FDA+

FDA asks Bio­gen and Ei­sai to pro­vide more da­ta on sub­cu­ta­neous Leqem­bi

Last year
Pharma
FDA+

Q&A: In­sitro CEO Daphne Koller on ‘po­ten­tial­ly de­struc­tive’ AI hype, Nvidi­a's chips, and biotech's da­ta prob­lem

Last year
People
R&D

Con­tineum says it will seek $136M in IPO to back its mid-stage neu­ro drug

Last year
Financing
Startups

Car­lyle’s Abing­worth will help fund Te­va’s Phase 3 asth­ma res­cue in­haler

Last year
Deals
R&D

Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

Last year
R&D
Pharma

FDA gives the green light to As­traZeneca's rare blood dis­or­der drug Voydeya, fol­low­ing ap­proval in Japan

Last year
FDA+

Wal­greens re­ports a $5.8B charge due to clin­ic op­er­a­tor Vil­lageMD

Last year
Health Tech

Genen­tech paves path to in­creased clin­i­cal tri­al di­ver­si­ty as a ‘busi­ness im­per­a­tive’

Last year
Pharma
Marketing

J&J can try again to dis­pute ev­i­dence in mul­ti­dis­trict talc lit­i­ga­tion

Last year
Pharma
Law

Nestlé Health Sci­ence plots next steps for C. diff drug Vow­st af­ter ro­bust up­take

Last year
Pharma
Marketing

Up­dat­ed: US in­tel­li­gence of­fi­cials told Con­gress that WuXi trans­ferred IP to Chi­nese au­thor­i­ties — re­port

Last year
China
Pharma

Gilead scores ex­pand­ed la­bel for he­pati­tis B drug Vem­lidy in chil­dren 6 years and old­er

Last year
Pharma
FDA+

WuXi AppTec, WuXi Bi­o­log­ics con­tin­ue to build out US pres­ence de­spite po­lit­i­cal ten­sions 

Last year
China
Manufacturing
First page Previous page 178179180181182183184 Next page Last page
A service from the Financial Times